Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ExpreS2ion Biotech Holding AB's enterprise value is kr-32.46 Mil.
ExpreS2ion Biotech Holding AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr-41.89 Mil. Therefore, ExpreS2ion Biotech Holding AB's EV-to-EBITDA for today is 0.77.
The historical rank and industry rank for ExpreS2ion Biotech Holding AB's EV-to-EBITDA or its related term are showing as below:
OSTO:EXPRS2'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.44 Med: -4.07 Max: 0.77
Current: 0.77
During the past 13 years, the highest EV-to-EBITDA of ExpreS2ion Biotech Holding AB was 0.77. The lowest was -43.44. And the median was -4.07.
OSTO:EXPRS2's EV-to-EBITDA is ranked better than 78.8% of 415
companies
in the Biotechnology industry
Industry Median: 11.92
vs OSTO:EXPRS2: 0.77
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ExpreS2ion Biotech Holding AB's PE Ratio (TTM) for today is calculated as:
ExpreS2ion Biotech Holding AB's share price for today is kr1.39.
ExpreS2ion Biotech Holding AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-4.316.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:EXPRS2 vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ExpreS2ion Biotech Holding AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ExpreS2ion Biotech Holding AB's EV-to-EBITDA falls into.
ExpreS2ion Biotech Holding AB's current Enterprise Value is kr-32.46 Mil.
ExpreS2ion Biotech Holding AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-41.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) has a EV-to-EBITDA of 0.77 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ExpreS2ion Biotech Holding AB. According to the industry distribution chart, ExpreS2ion Biotech Holding AB ranks #88 out of 415 companies in the Biotechnology industry, placing it in the top 21.2%.
Is ExpreS2ion Biotech Holding AB's EV-to-EBITDA too high?
ExpreS2ion Biotech Holding AB's current EV-to-EBITDA is 0.77. The Biotechnology industry median EV-to-EBITDA is 11.92. ExpreS2ion Biotech Holding AB's value of 0.77 is 93.5% below this industry median. Based on the distribution chart, ExpreS2ion Biotech Holding AB ranks #88 out of 415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ExpreS2ion Biotech Holding AB ranks #88 out of 415 companies for EV-to-EBITDA. This places ExpreS2ion Biotech Holding AB in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 11.92. ExpreS2ion Biotech Holding AB's value of 0.77 is 93.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.92, based on 415 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ExpreS2ion Biotech Holding AB's current EV-to-EBITDA of 0.77 is 93.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ExpreS2ion Biotech Holding AB. For the Biotechnology industry, the median EV-to-EBITDA is 11.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ExpreS2ion Biotech Holding AB's current EV-to-EBITDA is 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) is currently considered Possible Value Trap. The stock's GF Value™ is kr3.39, compared to a current price of kr1.39 — trading 59% below its estimated fair value. The current EV-to-EBITDA is 0.77 and 93.5% below the Biotechnology industry median of 11.92. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (OSTO:EXPRS2), the current EV-to-EBITDA is 0.77 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Overvalued in 2026?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued.
The current stock price of kr1.39 is trading 59% below its estimated GF Value™ of kr3.39.
GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.
Key valuation signals for OSTO:EXPRS2:
EV-to-EBITDA: 0.77
GF Value™: kr3.39 vs. price of kr1.39 (59% below fair value)
Industry Position: 93.5% below the Biotechnology median (#88 of 415)
No single metric tells the full story. See the OSTO:EXPRS2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score
Get the complete analysis for OSTO:EXPRS2
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EXPRS2 has been successfully added to your 
